• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,100.47 109.25
( 0.14%)
Global Indices
Nasdaq
51,927.61 57.71
(0.11%)
Dow Jones
7,374.18 -5.04
(-0.07%)
Hang Seng
69,065.93 -3,300.41
(-4.56%)
Nikkei 225
10,515.14 -14.75
(-0.14%)
Forex
USD-INR
94.55 -0.19
(-0.20%)
EUR-INR
107.36 -0.64
(-0.59%)
GBP-INR
124.56 -0.65
(-0.52%)
JPY-INR
0.58 0.00
(-0.30%)

EQUITY - MARKET SCREENER

Natco Pharma Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
524816
INE987B01026
477.507017
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
NATCOPHARM
12.63
16181.68
EPS(TTM)
Face Value()
Div & Yield %
71.55
2
0.55
 

Balkrishna Industries Deputy CFO Ravi Narayan Joshi resigns
Jun 24,2026
According to the company, Joshi's resignation will be effective from the close of business hours on 25 July 2026. In his resignation letter, he stated that that the decision was taken to pursue the next phase of his professional journey.

Balkrishna Industries is engaged in the business of manufacturing and selling 'off-highway tyres' (OHT) in the specialist segments such as agricultural, industrial & construction, earthmovers & port, mining, forestry, lawn & garden and all-terrain vehicles (ATV).

The company’s standalone net profit fell 18.5% to Rs 295.09 crore despite a 7.08% increase in revenue from operations to Rs 2,941.15 crore in Q4 FY26 over Q4 FY25.

The counter rose 0.29% to Rs 2,225.55 on the BSE.